Renalytix Management
Management criteria checks 1/4
Renalytix's CEO is James McCullough, appointed in Mar 2018, has a tenure of 6.33 years. total yearly compensation is $1.04M, comprised of 58% salary and 42% bonuses, including company stock and options. directly owns 1.78% of the company’s shares, worth $381.97K. The average tenure of the management team and the board of directors is 3.3 years and 0.9 years respectively.
Key information
James McCullough
Chief executive officer
US$1.0m
Total compensation
CEO salary percentage | 58.0% |
CEO tenure | 6.3yrs |
CEO ownership | 1.8% |
Management average tenure | 3.3yrs |
Board average tenure | less than a year |
Recent management updates
Recent updates
Renalytix: The Investment Case Is Shot
Jul 25Renalytix AI GAAP EPS of -$0.20, revenue of $0.81M
Jun 30Renalytix: High Growth Artificial Intelligence Play, Nearing A Possible Breakout
Apr 05Renalytix: Laying The Foundations For Growth
Jan 05Renalytix: Building Out A Capability To Ramp Revenue
Oct 20Renalytix AI EPS beats by $0.06, misses on revenue
Jun 15Centers for Medicaid & Medicare establishes MICT pathway
Jan 13Exact and Exact Sciences trade higher; Seen as beneficiaries from new CMS rule
Jan 12Renalytix AI EPS misses by $0.04
Nov 25CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$37m |
Dec 31 2023 | n/a | n/a | -US$42m |
Sep 30 2023 | n/a | n/a | -US$44m |
Jun 30 2023 | US$1m | US$601k | -US$46m |
Mar 31 2023 | n/a | n/a | -US$40m |
Dec 31 2022 | n/a | n/a | -US$42m |
Sep 30 2022 | n/a | n/a | -US$47m |
Jun 30 2022 | US$636k | US$601k | -US$45m |
Mar 31 2022 | n/a | n/a | -US$50m |
Dec 31 2021 | n/a | n/a | -US$44m |
Sep 30 2021 | n/a | n/a | -US$38m |
Jun 30 2021 | US$1m | US$586k | -US$35m |
Mar 31 2021 | n/a | n/a | -US$28m |
Dec 31 2020 | n/a | n/a | -US$20m |
Sep 30 2020 | n/a | n/a | -US$16m |
Jun 30 2020 | US$488k | US$470k | -US$10m |
Mar 31 2020 | n/a | n/a | US$28m |
Dec 31 2019 | n/a | n/a | -US$8m |
Sep 30 2019 | n/a | n/a | -US$5m |
Jun 30 2019 | US$216k | US$269k | -US$42m |
Compensation vs Market: James's total compensation ($USD1.04M) is above average for companies of similar size in the US market ($USD683.22K).
Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.
CEO
James McCullough (56 yo)
6.3yrs
Tenure
US$1,036,321
Compensation
Mr. James R. McCullough, M.B.A. is Co-Founder and has been the Chief Executive Officer of Renalytix Plc (formerly, Renalytix AI plc) since March 15, 2018 and served as its Executive Director. Mr. McCulloug...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Chief Executive Officer | 6.3yrs | US$1.04m | 1.78% $ 382.0k | |
Chief Technology Officer | 6.3yrs | no data | 0.37% $ 79.2k | |
President | less than a year | no data | no data | |
Interim CFO & Principal Accounting Officer | less than a year | no data | no data | |
Company Secretary | no data | no data | no data |
3.3yrs
Average Tenure
59.5yo
Average Age
Experienced Management: RNLX's management team is considered experienced (3.3 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Independent Non-Executive Director | 2.9yrs | US$24.00k | 0% $ 0 | |
Independent Non-Executive Director | 5.7yrs | US$24.00k | no data | |
Independent Non-Executive Chairman | 6.3yrs | US$24.00k | 6.52% $ 1.4m | |
Member of Clinical Advisory Board | less than a year | no data | no data | |
Member of Clinical Advisory Board | less than a year | no data | no data | |
Member of Clinical Advisory Board | less than a year | no data | no data | |
Member of Clinical Advisory Board | no data | no data | no data | |
Member of Clinical Advisory Board | 4.9yrs | no data | no data | |
Independent Non-Executive Director | 1.1yrs | no data | 0% $ 0 | |
Member of Clinical Advisory Board | less than a year | no data | no data | |
Member of Clinical Advisory Board | less than a year | no data | no data | |
Member of Clinical Advisory Board | less than a year | no data | no data |
0.9yrs
Average Tenure
64.5yo
Average Age
Experienced Board: RNLX's board of directors are not considered experienced ( 0.9 years average tenure), which suggests a new board.